Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
You may also be interested in...
Even with market estimates that NASH drugs eventually could command sales of $35 billion a year, some of the candidates and companies now competing in the space will have to be weeded out.
Numerous companies vie to become first to market with a therapy for the unmet medical need, which can lead to fibrosis, cirrhosis and need for a liver transplant. FDA may allow surrogate endpoints in pivotal trials to speed up approval of initial NASH therapies.
Companies big and small are making deals and advancing candidates to address an unmet medical need thought to have a vast undiagnosed patient base in the U.S. and Europe.